United Asset Strategies Inc. Reduces Stock Position in Humacyte, Inc. (NASDAQ:HUMA)

United Asset Strategies Inc. trimmed its holdings in Humacyte, Inc. (NASDAQ:HUMA) by 15.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 184,208 shares of the company’s stock after selling 34,100 shares during the quarter. United Asset Strategies Inc.’s holdings in Humacyte were worth $930,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. State Street Corp grew its position in shares of Humacyte by 66.1% in the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after purchasing an additional 1,895,529 shares in the last quarter. Millennium Management LLC boosted its stake in Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after purchasing an additional 1,334,641 shares during the period. Renaissance Technologies LLC grew its holdings in Humacyte by 693.0% during the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after buying an additional 524,600 shares in the last quarter. Marshall Wace LLP increased its position in shares of Humacyte by 3,301.5% during the second quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock valued at $2,226,000 after buying an additional 450,031 shares during the period. Finally, AQR Capital Management LLC boosted its position in shares of Humacyte by 1,018.4% in the second quarter. AQR Capital Management LLC now owns 256,342 shares of the company’s stock valued at $1,230,000 after acquiring an additional 233,422 shares during the period. Institutional investors own 44.71% of the company’s stock.

Insider Buying and Selling

In other Humacyte news, Director Brady W. Dougan sold 427,459 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the transaction, the director now owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Laura E. Niklason sold 811,172 shares of the stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the sale, the chief executive officer now owns 2,419,712 shares of the company’s stock, valued at approximately $10,743,521.28. This represents a 25.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,500,000 shares of company stock valued at $6,606,799 over the last three months. 11.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on HUMA shares. BTIG Research reaffirmed a “buy” rating and set a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. Benchmark upped their price objective on shares of Humacyte from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, December 23rd. D. Boral Capital reissued a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research note on Tuesday, January 21st. TD Cowen restated a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. Finally, Piper Sandler set a $6.00 price objective on Humacyte and gave the stock a “neutral” rating in a report on Friday, October 18th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Humacyte presently has an average rating of “Buy” and an average price target of $13.71.

Humacyte Trading Down 2.2 %

Shares of NASDAQ:HUMA opened at $4.51 on Tuesday. The stock has a market capitalization of $567.62 million, a P/E ratio of -3.37 and a beta of 1.32. The stock’s 50-day moving average price is $4.51 and its 200-day moving average price is $5.62. Humacyte, Inc. has a 12-month low of $2.81 and a 12-month high of $9.97.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.08). During the same period last year, the company posted ($0.25) earnings per share. As a group, research analysts predict that Humacyte, Inc. will post -1.27 EPS for the current year.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.